0.29
+7.41%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cleo Diagnostics
Its shares trade on ASX under the ticker COV.AX. It has been listed since 22 August 2023. In the fiscal year to 30 June 2025, it reported revenue of A$1.2m and a net loss of A$4.0m. At that date it held total assets of A$6.9m and shareholders' equity of A$5.8m.
Cleo Diagnostics Ltd is a AU-based company operating in industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2023-08-22. Cleo Diagnostics Ltd is an Australia-based medical diagnostics company. The firm is focussed on the development of non-invasive blood based In vitro diagnostics (IVD) tests to detect the presence, and recurrence, of ovarian cancer. The firm has developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant. Recurrence Test is a post-surgical test to identify whether a cancer is recurring following surgical removal and chemotherapy of a primary tumour. Screening Test is a screening test to identify early-stage ovarian cancer in women who do not present any symptoms consistent with ovarian cancer. The firm also offers the CLEO Test Kit, which is designed to detect a novel protein biomarker, CXCL10 in the blood.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 22 Aug 2023
- Website
- cleodx.com ↗
Leadership
Pay as last reported
- Mr. Adrien WingNon-Executive Chairman of the BoardA$80,080
- Dr. Richard AllmanChief Executive Officer, Executive Director, since 2022A$145,228
- Dr. Andrew StephensChief Scientific Officer, Executive Director, since 2022A$94,025
- Prof. Thomas JoblingNon-Executive Independent Director, Lead Medical Advisor, since 2022
- Ms. Pauline MoffattCompany Secretary
- Ms. Lucinda NolanNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cleo Diagnostics Ltd is an Australia-based medical diagnostics company headquartered in Melbourne.
- The company has developed a three-phased product development strategy for ovarian cancer detection tests.
- Cleo Diagnostics Ltd offers the CLEO Test Kit designed to detect CXCL10 protein biomarker in blood.
Weaknesses
- The company's sector and industry are listed as N/A in the provided information.
- The company went public via IPO on 2023-08-22, indicating a relatively new public market presence.
- The company's website is provided but no additional details about its market position or financial performance are given.
Opportunities
- The company's focus on non-invasive blood-based IVD tests for ovarian cancer detection presents a potential market opportunity.
- The three-phased product development strategy could lead to multiple revenue streams from different tests.
- The CLEO Test Kit targeting CXCL10 biomarker may address an unmet medical need in ovarian cancer detection.
Threats
- The company's sector and industry being listed as N/A may indicate challenges in market positioning or regulatory classification.
- The company's IPO in 2023 suggests it may face challenges in establishing a strong market presence quickly.
- The medical diagnostics industry is highly competitive with potential regulatory hurdles for new diagnostic tests.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.